Elevation Oncology (ELEV) Competitors $0.38 0.00 (-1.19%) Closing price 04:00 PM EasternExtended Trading$0.38 0.00 (-0.05%) As of 04:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ELEV vs. PLRX, ZURA, XBIT, IVVD, OKYO, ADAG, ORMP, CABA, ELUT, and MGXShould you be buying Elevation Oncology stock or one of its competitors? The main competitors of Elevation Oncology include Pliant Therapeutics (PLRX), Zura Bio (ZURA), XBiotech (XBIT), Invivyd (IVVD), OKYO Pharma (OKYO), Adagene (ADAG), Oramed Pharmaceuticals (ORMP), Cabaletta Bio (CABA), Elutia (ELUT), and Metagenomi (MGX). These companies are all part of the "pharmaceutical products" industry. Elevation Oncology vs. Its Competitors Pliant Therapeutics Zura Bio XBiotech Invivyd OKYO Pharma Adagene Oramed Pharmaceuticals Cabaletta Bio Elutia Metagenomi Pliant Therapeutics (NASDAQ:PLRX) and Elevation Oncology (NASDAQ:ELEV) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, valuation and profitability. Which has stronger valuation & earnings, PLRX or ELEV? Elevation Oncology is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPliant TherapeuticsN/AN/A-$210.30M-$3.61-0.39Elevation OncologyN/AN/A-$44.49M-$0.82-0.46 Does the media prefer PLRX or ELEV? In the previous week, Elevation Oncology had 1 more articles in the media than Pliant Therapeutics. MarketBeat recorded 2 mentions for Elevation Oncology and 1 mentions for Pliant Therapeutics. Pliant Therapeutics' average media sentiment score of 1.81 beat Elevation Oncology's score of 0.24 indicating that Pliant Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Pliant Therapeutics Very Positive Elevation Oncology Neutral Which has more risk & volatility, PLRX or ELEV? Pliant Therapeutics has a beta of 1.3, indicating that its share price is 30% more volatile than the S&P 500. Comparatively, Elevation Oncology has a beta of 1.48, indicating that its share price is 48% more volatile than the S&P 500. Do analysts prefer PLRX or ELEV? Pliant Therapeutics currently has a consensus target price of $13.31, suggesting a potential upside of 837.50%. Elevation Oncology has a consensus target price of $3.39, suggesting a potential upside of 802.38%. Given Pliant Therapeutics' higher probable upside, equities research analysts plainly believe Pliant Therapeutics is more favorable than Elevation Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pliant Therapeutics 0 Sell rating(s) 12 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Elevation Oncology 0 Sell rating(s) 11 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is PLRX or ELEV more profitable? Pliant Therapeutics' return on equity of -67.56% beat Elevation Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Pliant TherapeuticsN/A -67.56% -52.54% Elevation Oncology N/A -74.68%-48.14% Do institutionals & insiders believe in PLRX or ELEV? 97.3% of Pliant Therapeutics shares are held by institutional investors. Comparatively, 83.7% of Elevation Oncology shares are held by institutional investors. 8.0% of Pliant Therapeutics shares are held by company insiders. Comparatively, 8.1% of Elevation Oncology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummaryElevation Oncology beats Pliant Therapeutics on 6 of the 11 factors compared between the two stocks. Get Elevation Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for ELEV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ELEV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELEV vs. The Competition Export to ExcelMetricElevation OncologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$22.22M$2.93B$5.50B$9.39BDividend YieldN/A2.46%4.25%4.09%P/E Ratio-0.4620.3128.1019.86Price / SalesN/A261.57402.2879.25Price / CashN/A42.3835.5357.53Price / Book0.377.838.265.72Net Income-$44.49M-$55.11M$3.24B$257.80M7 Day Performance-0.90%2.18%0.50%1.06%1 Month Performance-1.68%12.98%7.99%11.30%1 Year Performance-87.02%1.98%28.68%17.00% Elevation Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELEVElevation Oncology2.8409 of 5 stars$0.38-1.2%$3.39+802.4%-87.3%$22.22MN/A-0.4640PLRXPliant Therapeutics4.4766 of 5 stars$1.45+2.8%$13.31+818.1%-90.1%$89.02M$1.58M-0.4090Positive NewsZURAZura Bio2.875 of 5 stars$1.30-0.8%$14.33+1,002.6%-66.1%$88.89MN/A-1.863XBITXBiotech1.6969 of 5 stars$2.89+2.1%N/A-54.6%$88.12M$4.01M-2.24100Positive NewsIVVDInvivyd3.6892 of 5 stars$0.73-1.2%$5.85+701.4%-50.6%$87.57M$36.69M-0.61100Positive NewsOKYOOKYO Pharma3.1334 of 5 stars$2.58-8.2%$7.00+171.3%+89.1%$87.30MN/A0.007Trending NewsGap DownADAGAdagene2.518 of 5 stars$1.85-3.1%$8.00+332.4%-24.2%$87.15M$100K0.00260Upcoming EarningsORMPOramed Pharmaceuticals1.2191 of 5 stars$2.13-0.5%N/A-17.6%$87.01M$1.34M-4.8410Positive NewsCABACabaletta Bio2.9507 of 5 stars$1.69-2.9%$14.43+753.8%-78.5%$85.75MN/A-0.6750News CoverageELUTElutia3.7047 of 5 stars$2.05-14.2%$8.00+290.2%-54.2%$84.30M$24.38M-1.06180Positive NewsMGXMetagenomi2.9144 of 5 stars$2.25+3.2%$13.00+477.8%-60.0%$84.11M$52.29M-1.07236 Related Companies and Tools Related Companies PLRX Alternatives ZURA Alternatives XBIT Alternatives IVVD Alternatives OKYO Alternatives ADAG Alternatives ORMP Alternatives CABA Alternatives ELUT Alternatives MGX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ELEV) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elevation Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Elevation Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ELEV Stock Alerts